Medicalgorithmics S.A. — Earnings Release 2026

Apr 9, 2026

Report Content Subject: PLN 10.2 million in sales revenue (+51% YoY) and positiveEBITDA - selected estimated financial data of the MedicalgorithmicsCapital Group for Q1 2026

Current Report No.: 11/2026

Date of preparation: 9 April 2026

Legal basis: Article 17(1) of the MAR Regulation - inside information

Medicalgorithmics S.A., with its registered office in Warsaw (the"Company", the "Issuer"), hereby announces that in the first quarter of2026, the estimated, unaudited consolidated sales revenue of theMedicalgorithmics Capital Group amounted to a total of PLN 10,194thousand, including PLN 4,678 thousand generated in the U.S. market,while the number of sessions, i.e. ECG analyses performed using theCompany's systems reached 112,058 sessions. The preliminary estimatedEBITDA (operating result increased by depreciation and amortization) forthis period amounted to PLN 1,006 thousand.

For comparison, in the first quarter of the previous calendar year,these figures were as follows: sales revenue of PLN 6,769 thousand,including PLN 2,280 thousand in the U.S. market; the number of sessionsreached 91,780; EBITDA for that period was negative and amounted to PLN-3,100 thousand.

The Management Board emphasizes that this report contains estimated datathat may change as a result of further financial reporting procedures.Final information regarding the consolidated sales revenue achieved inQ1 2026, including in the U.S. market, the number of sessions completedby the Company in this period, and EBITDA will be presented in theinterim condensed consolidated financial statements of theMedicalgorithmics Capital Group for Q1 2026.

The Management Board also announces that it has decided to publishsimilar estimated data immediately after the end of each subsequentquarter - as soon as such data is prepared, but no later than by themiddle of the month following the end of the given calendar quarter.